Abstract: This poster demonstrates the automation of a 96-well homogeneous bioluminescent TNFa blocker bioassay based on quantification of caspase 3 activity. The bioassay can be performed in a single day, and uses single-use, frozen U937 (human) cells which exhibit rapid response to TNFa. A simple, yet robust liquid handler was used to automate the assay steps of antibody titration and of cell and reagent dispensing.Summary: TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.